Neuroimaging standards for research into small vessel disease—advances since 2013¶

One-paragraph summary¶

STRIVE-2 updates standardized SVD imaging terminology, acquisition, quantitative markers, and interpretation, explicitly integrating advances since the original 2013 STRIVE statement and the overlap between SVD, aging, and neurodegeneration (Duering 2023, PMID 37236211).

Key findings¶

Retains common visible lesion vocabulary.
Extends attention to quantitative and advanced imaging.
Emphasizes longitudinal and cross-disease interpretation.
Frames imaging biomarkers as candidates requiring validation.

Limitations¶

Standards do not make a marker diagnostic or a surrogate endpoint.
Scanner and pipeline harmonization remain major obstacles.

Why it matters¶

It is the technical language shared by the SVD, imaging, biomarker, and trial pages.

Cited by wiki pages¶

Small-vessel disease
Neuroimaging
Biomarkers